Orforglipron and semaglutide both act on the GLP-1 receptor and nothing else, but they are built and delivered very differently. Orforglipron is a non-peptide small molecule taken once daily as a pill, while semaglutide is an injectable peptide given once weekly under brands like Ozempic and Wegovy. They are also at different regulatory stages, so the evidence behind each is not on equal footing.
Reviewed for accuracy · Last reviewed July 8, 2026The most concrete difference is format and regulatory status. Semaglutide is FDA-approved, has defined labeled titrations, and is given as a once-weekly injection. Orforglipron is a once-daily oral small molecule that had completed its Phase 3 program and was under FDA review as of 2026, so it did not yet have an approved label at that time. Confirm its current status with an authoritative source rather than this page.
Mechanistically the two are closer than their formats suggest: both act only on the GLP-1 receptor to slow gastric emptying and reduce appetite. The headline practical contrast is a daily pill with no reported food or water timing restrictions versus a weekly subcutaneous peptide that, when sourced as a vial, involves reconstitution and unit conversions.
Both reported predominantly gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) that were generally mild to moderate and concentrated during dose escalation, a pattern common across GLP-1 receptor agonists. None of this is a substitute for medical advice about which, if either, is appropriate.
This page is an independent educational reference and is not medical advice. Talk to a doctor before starting or adjusting any compound.